Free Trial
Ends Tomorrow! Last Chance to Get MarketBeat All Access at $149
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion

Chinese Stocks To Research - October 29th

Diageo logo with Consumer Staples background
Image from MarketBeat Media, LLC.

Key Points

  • MarketBeat’s screener identified seven high-dollar-volume stocks to watch: Diageo (DEO), UP Fintech (TIGR), Universe Pharmaceuticals (UPC), Regencell Bioscience (RGC), RBB Bancorp (RBB), China SXT Pharmaceuticals (SXTC), and BGM Group (BGM).
  • The companies span alcoholic beverages, online brokerage, banking, and pharmaceuticals, with several focused on traditional Chinese medicine and related products.
  • Investors considering these China-linked stocks should account for regulatory, geopolitical, market-access, and economic risks in addition to company-specific factors.
  • MarketBeat previews the top five stocks to own by November 1st.

Diageo, UP Fintech, Universe Pharmaceuticals, Regencell Bioscience, RBB Bancorp, China SXT Pharmaceuticals, and BGM Group are the seven Chinese stocks to watch today, according to MarketBeat's stock screener tool. Chinese stocks are shares of publicly traded companies based in China or whose primary business operations and economic exposure are tied to China. Investors may access them through mainland exchanges in Shanghai and Shenzhen, or through listings in Hong Kong and overseas markets, and should consider factors such as government regulation, geopolitical risk, market-access restrictions, and economic conditions. These companies had the highest dollar trading volume of any Chinese stocks within the last several days.

Diageo (DEO)

Diageo plc, together with its subsidiaries, engages in the production, marketing, and sale of alcoholic beverages. The company offers scotch, gin, vodka, rum, raki, liqueur, wine, tequila, Chinese white spirits, cachaça, and brandy, as well as beer, including cider and flavored malt beverages. It also provides Chinese, Canadian, Irish, American, and Indian-Made Foreign Liquor whiskies, as well as flavored malt beverages, ready to drink, and non-alcoholic products.

Read Our Latest Research Report on DEO

UP Fintech (TIGR)

UP Fintech Holding Limited provides online brokerage services focusing on Chinese investors. The company has developed a brokerage platform, which allows investor to trade stocks, options, warrants, and other financial instruments that can be accessed through its APP and website. It offers brokerage and value-added services, including investor education, community engagement, and IR platform services.

Read Our Latest Research Report on TIGR

Universe Pharmaceuticals (UPC)

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.

Read Our Latest Research Report on UPC

Regencell Bioscience (RGC)

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.

Read Our Latest Research Report on RGC

RBB Bancorp (RBB)

RBB Bancorp operates as the bank holding company for Royal Business Bank that provides various banking products and services to the Chinese-American, Korean-American, and other Asian-American communities. Its deposit products include checking, savings, and money market accounts, as well as certificates of deposit.

Read Our Latest Research Report on RBB

China SXT Pharmaceuticals (SXTC)

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.

Read Our Latest Research Report on SXTC

BGM Group (BGM)

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.

Read Our Latest Research Report on BGM

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Diageo Right Now?

Before you consider Diageo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diageo wasn't on the list.

While Diageo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines